Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Preventions ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

It is unclear how new members of the panel have been vetted for conflicts of interest. Read more at straitstimes.com. Read ...

The NIH halted its policy requiring universities and research institutes to certify they do not have unlawful diversity, ...

A series of new revelations has come to light about the FDA's delay in granting full approval to Novavax's COVID-19 shot, thanks to recent reporting from the Wall Street Journal and STAT News.

Major vaccine policy changes could be on the horizon as the HHS removes key advisors. Click for my thoughts on what this may ...

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...

The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by rising vaccine uptake, impr ...